It was also found by sequencing that SLC1A5, a glutamine transporter target of FTO, could selectively affect the survival and proliferation of tumor cells by stimulating metabolic reprogramming of VHL-deficient ccRCC cells [115]. This evidence concerns the gene FTO and nonpapillary renal cell carcinoma.